Cartesian Therapeutics, Inc.
http://www.cartesiantherapeutics.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Cartesian Therapeutics, Inc.
Finance Watch: US Market May Warm To Go-Public Options As Summer Progresses
Public Company Edition: The IPO market in the US cooled in Q2, but a warm-up may come in Q3 alongside new SPAC merger opportunities; Artiva may be the next biopharma firm to go public. Also, IDEAYA and Recursion grossed $302.4m and $200m, respectively, in follow-on offerings.
Cartesian Looks To Chart The Way For CAR-T In Autoimmune Disease
A Phase IIb trial testing Cartesian’s autologous mRNA-engineered CAR-T therapy for the treatment of generalized myasthenia gravis (MG) met the primary endpoint.
Astellas CStO Pearson: We’re Not Short Of Opportunities To Compensate For LOEs
Astellas’ chief strategy officer, Adam Pearson, talks to Scrip about the company’s launch execution thrust for key therapies ahead of the loss of exclusivity for Xtandi and also deal-making appetite and choices, including the Iveric Bio buyout and walking away from the collaboration with Cartesian Therapeutics.
CGT Landscape: Recent Approvals, Deals And 2024 Catalysts
The last quarter of 2023 was an exciting one for the cell and gene therapy sector – with the first-ever approval for a CRISPR-based therapeutic in the US and an increase in Phase III trials in the overall CGT pipeline.
Company Information
- Industry
- Biotechnology
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice